

Aimee Payne

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2102693/publications.pdf>

Version: 2024-02-01

74
papers

3,851
citations

136950

32
h-index

133252

59
g-index

180
all docs

180
docs citations

180
times ranked

3842
citing authors

#	ARTICLE	IF	CITATIONS
1	Temporal Outcomes after Rituximab Therapy for Pemphigus Vulgaris. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1058-1064.e7.	0.7	9
2	Pemphigus and Pemphigoid: From Disease Mechanisms to Druggable Pathways. <i>Journal of Investigative Dermatology</i> , 2022, 142, 907-914.	0.7	21
3	Establishing cutoff values for mild, moderate and severe disease in patients with pemphigus using the Pemphigus Disease Area Index. <i>British Journal of Dermatology</i> , 2021, 184, 975-977.	1.5	2
4	Identifying the required degree of disease clearance to improve quality of life in pemphigus vulgaris. <i>British Journal of Dermatology</i> , 2021, 184, 573-575.	1.5	1
5	Updated international expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e412-e414.	2.4	28
6	B-cell targeted therapies in pemphigus. <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, .	0.2	1
7	Biological controls for standardization and interpretation of adaptive immune receptor repertoire profiling. <i>ELife</i> , 2021, 10, .	6.0	21
8	B-cell targeted therapies in pemphigus. <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, 161-173.	0.2	1
9	Diagnosis and management of pemphigus: Recommendations of an international panel of experts. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 575-585.e1.	1.2	224
10	Clinical outcome and safety of rituximab therapy for pemphigoid diseases. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1237-1239.	1.2	23
11	Custom dental trays with topical corticosteroids for management of gingival lesions of mucous membrane pemphigoid. <i>International Journal of Dermatology</i> , 2020, 59, e211-e213.	1.0	3
12	Comparison of C3d immunohistochemical staining to enzyme-linked immunosorbent assay and immunofluorescence for diagnosis of bullous pemphigoid. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 172-178.	1.2	11
13	Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e302-e303.	2.4	53
14	Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis. <i>Journal of Clinical Investigation</i> , 2020, 130, 2451-2464.	8.2	106
15	Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris. <i>Journal of Clinical Investigation</i> , 2020, 130, 6317-6324.	8.2	66
16	Detection of underlying dementia in bullous pemphigoid patients using cognitive evaluation tests: a multicenter case-control study. <i>Annals of Translational Medicine</i> , 2020, 8, 1397-1397.	1.7	4
17	Single-Cell Analysis Suggests that Ongoing Affinity Maturation Drives the Emergence of Pemphigus Vulgaris Autoimmune Disease. <i>Cell Reports</i> , 2019, 28, 909-922.e6.	6.4	31
18	Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus. <i>JAMA Dermatology</i> , 2019, 155, 1404.	4.1	42

#	ARTICLE	IF	CITATIONS
19	On the mark: genetically engineered immunotherapies for autoimmunity. <i>Current Opinion in Immunology</i> , 2019, 61, 69-73.	5.5	9
20	RPGRIPL is required for stabilizing epidermal keratinocyte adhesion through regulating desmoglein endocytosis. <i>PLoS Genetics</i> , 2019, 15, e1007914.	3.5	8
21	World Workshop on Oral Medicine <scp>VII</scp>: Immunobiologics for salivary gland disease in Sjögren's syndrome: A systematic review. <i>Oral Diseases</i> , 2019, 25, 102-110.	3.0	16
22	World Workshop of Oral Medicine VII: A systematic review of immunobiologic therapy for oral manifestations of pemphigoid and pemphigus. <i>Oral Diseases</i> , 2019, 25, 111-121.	3.0	13
23	Anti-BP180 Autoantibodies Are Present in Stroke and Recognize Human Cutaneous BP180 and BP180-NC16A. <i>Frontiers in Immunology</i> , 2019, 10, 236.	4.8	10
24	Assessing the Correlation Between Disease Severity Indices and Quality of Life Measurement Tools in Pemphigus. <i>Frontiers in Immunology</i> , 2019, 10, 2571.	4.8	13
25	Increasing the Complement of Therapeutic Options in Bullous Pemphigoid. <i>Journal of Investigative Dermatology</i> , 2018, 138, 246-248.	0.7	10
26	Authors' reply: Paraneoplastic autoimmune multiorgan syndrome and paraneoplastic pemphigus describe the same spectrum of disease pathology. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18013.	30.5	1
27	Mechanisms Causing Loss of Keratinocyte Cohesion in Pemphigus. <i>Journal of Investigative Dermatology</i> , 2018, 138, 32-37.	0.7	113
28	Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific Conference. <i>Frontiers in Medicine</i> , 2018, 5, 306.	2.6	27
29	Autoreactive IgG and IgA B Cells Evolve through Distinct Subclass Switch Pathways in the Autoimmune Disease Pemphigus Vulgaris. <i>Cell Reports</i> , 2018, 24, 2370-2380.	6.4	23
30	Proteomic Analysis of Pemphigus Autoantibodies Indicates a Larger, More Diverse, and More Dynamic Repertoire than Determined by B Cell Genetics. <i>Cell Reports</i> , 2017, 18, 237-247.	6.4	49
31	Pemphigus. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17026.	30.5	371
32	Meeting Report of the Pathogenesis of Pemphigus and Pemphigoid Meeting in Munich, September 2016. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1199-1203.	0.7	34
33	The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (<scp>CDASI</scp>) among dermatologists, rheumatologists and neurologists. <i>British Journal of Dermatology</i> , 2017, 176, 423-430.	1.5	19
34	Clinical significance of immunoglobulin E in bullous pemphigoid. <i>British Journal of Dermatology</i> , 2017, 177, 13-14.	1.5	2
35	2504. <i>Journal of Clinical and Translational Science</i> , 2017, 1, 10-10.	0.6	0
36	Exploring intentions of physician-scientist trainees: factors influencing MD and MD/PhD interest in research careers. <i>BMC Medical Education</i> , 2017, 17, 115.	2.4	38

#	ARTICLE	IF	CITATIONS
37	Rituximab therapy in pemphigus and other autoantibody-mediated diseases. <i>F1000Research</i> , 2017, 6, 83.	1.6	23
38	Setting the target for pemphigus vulgaris therapy. <i>JCI Insight</i> , 2017, 2, e92021.	5.0	30
39	Stat3 regulates desmoglein 3 transcription in epithelial keratinocytes. <i>JCI Insight</i> , 2017, 2, .	5.0	19
40	Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor. <i>PLoS Pathogens</i> , 2017, 13, e1006613.	4.7	106
41	Overcoming the Constraints of Anti-HIV/CD89 Bispecific Antibodies That Limit Viral Inhibition. <i>Journal of Immunology Research</i> , 2016, 2016, 1-5.	2.2	8
42	Determinants of VH1-46 Cross-Reactivity to Pemphigus Vulgaris Autoantigen Desmoglein 3 and Rotavirus Antigen VP6. <i>Journal of Immunology</i> , 2016, 197, 1065-1073.	0.8	21
43	Quantifying disease extent in pemphigus. <i>British Journal of Dermatology</i> , 2016, 175, 18-19.	1.5	1
44	Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 787-791.	1.3	63
45	Identifying the Target Cells and Mechanisms of Merkel Cell Polyomavirus Infection. <i>Cell Host and Microbe</i> , 2016, 19, 775-787.	11.0	133
46	Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. <i>Science</i> , 2016, 353, 179-184.	12.6	468
47	Pathogenicity and Epitope Characteristics Do Not Differ in IgG Subclass-Switched Anti-Desmoglein 3 IgG1 and IgG4 Autoantibodies in Pemphigus Vulgaris. <i>PLoS ONE</i> , 2016, 11, e0156800.	2.5	21
48	Reliability and Validity of Cutaneous Sarcoidosis Outcome Instruments Among Dermatologists, Pulmonologists, and Rheumatologists. <i>JAMA Dermatology</i> , 2015, 151, 1317.	4.1	21
49	The dual nature of interleukin-10 in pemphigus vulgaris. <i>Cytokine</i> , 2015, 73, 335-341.	3.2	26
50	Persistence of Anti-Desmoglein 3 IgG + B-Cell Clones in Pemphigus Patients over Years. <i>Journal of Investigative Dermatology</i> , 2015, 135, 742-749.	0.7	83
51	Nanorobotic Investigation Identifies Novel Visual, Structural and Functional Correlates of Autoimmune Pathology in a Blistering Skin Disease Model. <i>PLoS ONE</i> , 2014, 9, e106895.	2.5	17
52	Plakophilins, Desmogleins, and Pemphigus: The Tail Wagging the Dog. <i>Journal of Investigative Dermatology</i> , 2014, 134, 874-876.	0.7	2
53	MAPKAP Kinase 2 (MK2)-Dependent and -Independent Models of Blister Formation in Pemphigus Vulgaris. <i>Journal of Investigative Dermatology</i> , 2014, 134, 68-76.	0.7	47
54	Shared VH1-46 gene usage by pemphigus vulgaris autoantibodies indicates common humoral immune responses among patients. <i>Nature Communications</i> , 2014, 5, 4167.	12.8	63

#	ARTICLE	IF	CITATIONS
55	Reliability and Convergent Validity of the Cutaneous Sarcoidosis Activity and Morphology Instrument for Assessing Cutaneous Sarcoidosis. <i>JAMA Dermatology</i> , 2013, 149, 550.	4.1	40
56	Enrichment of total serum IgG4 in patients with pemphigus. <i>British Journal of Dermatology</i> , 2012, 167, 1245-1253.	1.5	59
57	Signaling Dependent and Independent Mechanisms in Pemphigus Vulgaris Blister Formation. <i>PLoS ONE</i> , 2012, 7, e50696.	2.5	89
58	p38 MAPK Activation Is Downstream of the Loss of Intercellular Adhesion in Pemphigus Vulgaris. <i>Journal of Biological Chemistry</i> , 2011, 286, 1283-1291.	3.4	72
59	Autoimmunity to Desmocollin 3 in Pemphigus Vulgaris. <i>American Journal of Pathology</i> , 2010, 177, 2724-2730.	3.8	82
60	Homologous regions of autoantibody heavy chain complementarity-determining region 3 (H-CDR3) in patients with pemphigus cause pathogenicity. <i>Journal of Clinical Investigation</i> , 2010, 120, 4111-4117.	8.2	51
61	Antibodies to the Desmoglein 1 Precursor Proprotein but Not to the Mature Cell Surface Protein Cloned from Individuals without Pemphigus. <i>Journal of Immunology</i> , 2009, 183, 5615-5621.	0.8	31
62	Disruption of Desmosome Assembly by Monovalent Human Pemphigus Vulgaris Monoclonal Antibodies. <i>Journal of Investigative Dermatology</i> , 2009, 129, 908-918.	0.7	60
63	Reliability and Convergent Validity of Two Outcome Instruments for Pemphigus. <i>Journal of Investigative Dermatology</i> , 2009, 129, 2404-2410.	0.7	183
64	The Neutralization Properties of a HIV-Specific Antibody Are Markedly Altered by Glycosylation Events Outside the Antigen-Binding Domain. <i>Journal of Immunology</i> , 2007, 178, 7132-7138.	0.8	37
65	Targeting Pemphigus Autoantibodies through their Heavy-Chain Variable Region Genes. <i>Journal of Investigative Dermatology</i> , 2007, 127, 1681-1691.	0.7	28
66	Cloning and genetic characterization of human pemphigus autoantibodies. <i>Journal of the American Academy of Dermatology</i> , 2006, 55, e2.	1.2	0
67	Pathogenic human monoclonal antibody against desmoglein 3. <i>Clinical Immunology</i> , 2006, 120, 68-75.	3.2	41
68	Dermatologic Toxicity of Chemotherapeutic Agents. <i>Seminars in Oncology</i> , 2006, 33, 86-97.	2.2	70
69	Two Novel TP63 Mutations Associated With the Ankyloblepharon, Ectodermal Defects, and Cleft Lip and Palate Syndrome. <i>Archives of Dermatology</i> , 2005, 141, 1567-73.	1.4	38
70	Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera: Implications for active and passive immunotherapy. <i>Journal of Medical Virology</i> , 2005, 76, 146-152.	5.0	6
71	Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display. <i>Journal of Clinical Investigation</i> , 2005, 115, 888-899.	8.2	198
72	Desmosomes and disease: pemphigus and bullous impetigo. <i>Current Opinion in Cell Biology</i> , 2004, 16, 536-543.	5.4	137

#	ARTICLE	IF	CITATIONS
73	Binding and Neutralization Activity of Human IgG1 and IgG3 from Serum of HIV-Infected Individuals. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 785-792.	1.1	37
74	Evidence of determinant spreading in the antibody responses to prostate cell surface antigens in patients immunized with prostate-specific antigen. <i>Clinical Cancer Research</i> , 2002, 8, 368-73.	7.0	26